{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:43:25Z","timestamp":1794908605598,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74571-2","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:34:28Z","timestamp":1782758068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Lauren P.","family":"Cobb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8023-4665","authenticated-orcid":false,"given":"Yibo","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-985X","authenticated-orcid":false,"given":"Max","family":"Molina Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6820-1456","authenticated-orcid":false,"given":"Nejla","family":"Ozirmak Lermi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-0860","authenticated-orcid":false,"given":"Sharia D.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrett Craig","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3239-6658","authenticated-orcid":false,"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-0266","authenticated-orcid":false,"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa Maren Solis","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":false,"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-5279","authenticated-orcid":false,"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Sanchez-Espiridion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7287-2877","authenticated-orcid":false,"given":"Minghao","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-1762","authenticated-orcid":false,"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolyn","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-4151","authenticated-orcid":false,"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"74571_CR1","doi-asserted-by":"publisher","unstructured":"Matsuo, K., Machida, H., Grubbs, B. H., Sood, A. K. & Gershenson, D. M. Trends of low-grade serous ovarian carcinoma in the United States. J. Gynecol. Oncol. 29, https:\/\/doi.org\/10.3802\/jgo.2018.29.e15 (2018).","DOI":"10.3802\/jgo.2018.29.e15"},{"key":"74571_CR2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","volume":"108","author":"KM Schmeler","year":"2008","unstructured":"Schmeler, K. M. et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 108, 510\u2013514 (2008).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","volume":"158","author":"LP Cobb","year":"2020","unstructured":"Cobb, L. P. et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol. Oncol. 158, 653\u2013658 (2020).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","volume":"140","author":"JP Grabowski","year":"2016","unstructured":"Grabowski, J. P. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol. Oncol. 140, 457\u2013462 (2016).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","volume":"114","author":"DM Gershenson","year":"2009","unstructured":"Gershenson, D. M. et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol. Oncol. 114, 48\u201352 (2009).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","volume":"33","author":"RN Grisham","year":"2023","unstructured":"Grisham, R. N. et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int. J. Gynecol. Cancer 33, 1331\u20131344 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"74571_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","volume":"125","author":"DM Gershenson","year":"2012","unstructured":"Gershenson, D. M. et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 125, 661\u2013666 (2012).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson, D. M. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J. Clin. Oncol. 35, 1103 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74571_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","volume":"108","author":"DM Gershenson","year":"2006","unstructured":"Gershenson, D. M. et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 108, 361\u2013368 (2006).","journal-title":"Obstet. Gynecol."},{"key":"74571_CR10","doi-asserted-by":"crossref","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncology 13, 417\u2013430 (2016).","DOI":"10.1038\/nrclinonc.2016.26"},{"key":"74571_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"74571_CR12","doi-asserted-by":"crossref","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet. Oncol. 17, 425\u2013439 (2016).","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"74571_CR13","doi-asserted-by":"crossref","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465\u20132472 (2018).","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"74571_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet. Oncol. 19, 904\u2013915 (2018).","journal-title":"Lancet. Oncol."},{"key":"74571_CR15","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge, G. W. et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875\u20132884 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74571_CR16","doi-asserted-by":"crossref","unstructured":"Sledge, G. W. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"74571_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/gutjnl-2018-318070","volume":"69","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 69, 18\u201331 (2020).","journal-title":"Gut"},{"key":"74571_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","volume":"165","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M. et al. The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes. Gynecol. Oncol. 165, 560\u2013567 (2022).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s41416-022-01897-1","volume":"127","author":"L Musacchio","year":"2022","unstructured":"Musacchio, L. et al. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). Br. J. Cancer 127, 1479\u20131486 (2022).","journal-title":"Br. J. Cancer"},{"key":"74571_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nri.2017.103","volume":"17","author":"CT Taylor","year":"2017","unstructured":"Taylor, C. T. & Colgan, S. P. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat. Rev. Immunol. 17, 774\u2013785 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"74571_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 8, 70 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"74571_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.celrep.2013.01.010","volume":"3","author":"H Mohammed","year":"2013","unstructured":"Mohammed, H. et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 3, 342\u2013349 (2013).","journal-title":"Cell Rep."},{"key":"74571_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","volume":"78","author":"Y Wu","year":"2018","unstructured":"Wu, Y. et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ER\u03b1-GREB1 transcriptional axis. Cancer Res. 78, 671\u2013684 (2018).","journal-title":"Cancer Res."},{"key":"74571_CR24","doi-asserted-by":"publisher","unstructured":"Shin, E. M. et al. GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ER\u03b1 glycosylation and stability to cancer. Sci. Adv. 7, https:\/\/doi.org\/10.1126\/sciadv.abe2470 (2021).","DOI":"10.1126\/sciadv.abe2470"},{"key":"74571_CR25","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1038\/s41388-018-0377-y","volume":"37","author":"K Hodgkinson","year":"2018","unstructured":"Hodgkinson, K. et al. GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. Oncogene 37, 5873\u20135886 (2018).","journal-title":"Oncogene"},{"key":"74571_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2005.12.016","volume":"21","author":"ASL Cheng","year":"2006","unstructured":"Cheng, A. S. L. et al. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol. Cell 21, 393\u2013404 (2006).","journal-title":"Mol. Cell"},{"key":"74571_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-020-00880-8","volume":"13","author":"Q Du","year":"2020","unstructured":"Du, Q. et al. The application and prospect of CDK4\/6 inhibitors in malignant solid tumors. J. Hematol. Oncol. 13, 41 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"74571_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00697-5","volume":"10","author":"AD Elias","year":"2024","unstructured":"Elias, A. D. et al. Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+\/Her2- breast cancer. NPJ Breast Cancer 10, 88 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"74571_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4143\/crt.2023.1251","volume":"57","author":"Q Shao","year":"2025","unstructured":"Shao, Q. et al. A single-arm phase II clinical trial of fulvestrant combined with neoadjuvant chemotherapy of ER+\/HER2- locally advanced breast cancer: integrated analysis of 18F-FES PET-CT and metabolites with treatment response. Cancer Res. Treat. 57, 126\u2013139 (2025).","journal-title":"Cancer Res. Treat."},{"key":"74571_CR30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","volume":"178","author":"J Guan","year":"2019","unstructured":"Guan, J. et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178, 949\u2013963 (2019).","journal-title":"Cell"},{"key":"74571_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6","volume":"13","author":"M Palafox","year":"2022","unstructured":"Palafox, M. et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer. Nat. Commun. 13, 5258 (2022).","journal-title":"Nat. Commun."},{"key":"74571_CR32","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"74571_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41588-022-01141-9","volume":"54","author":"D Barkley","year":"2022","unstructured":"Barkley, D. et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat. Genet. 54, 1192\u20131201 (2022).","journal-title":"Nat. Genet."},{"key":"74571_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).","journal-title":"Science"},{"key":"74571_CR35","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-24-1999","volume":"31","author":"AK Green","year":"2025","unstructured":"Green, A. K. et al. A phase II study of fulvestrant plus abemaciclib in hormone receptor\u2013positive advanced or recurrent endometrial cancer. Clin. Cancer Res. 31, 2088\u20132096 (2025).","journal-title":"Clin. Cancer Res."},{"key":"74571_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","volume":"192","author":"MR Mirza","year":"2025","unstructured":"Mirza, M. R. et al. Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial. Gynecol. Oncol. 192, 128\u2013136 (2025).","journal-title":"Gynecol. Oncol."},{"key":"74571_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO-25-01348","volume":"44","author":"BM Slomovitz","year":"2026","unstructured":"Slomovitz, B. M. et al. Phase II trial of ribociclib plus letrozole in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum: a GOG partners trial (GOG 3026). J. Clin. Oncol. 44, 153\u2013163 (2026).","journal-title":"J. Clin. Oncol."},{"key":"74571_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000926","volume":"5","author":"G Colon-Otero","year":"2020","unstructured":"Colon-Otero, G. et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open 5, e000926 (2020).","journal-title":"ESMO Open"},{"key":"74571_CR39","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638\u20133646 (2017).","journal-title":"J. Clin. Oncol."},{"key":"74571_CR40","doi-asserted-by":"publisher","first-page":"102136","DOI":"10.1016\/j.ctrv.2020.102136","volume":"93","author":"I Migliaccio","year":"2021","unstructured":"Migliaccio, I. et al. CDK4\/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treat. Rev. 93, 102136 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"74571_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417\u2013430 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74571_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03431-x","volume":"22","author":"C Shi","year":"2024","unstructured":"Shi, C. et al. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification. BMC Med. 22, 215 (2024).","journal-title":"BMC Med."},{"key":"74571_CR43","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/carcin\/bgaa096","volume":"41","author":"CN Haines","year":"2020","unstructured":"Haines, C. N., Klingensmith, H. D., Komara, M. & Burd, C. J. GREB1 regulates PI3K\/Akt signaling to control hormone-sensitive breast cancer proliferation. Carcinogenesis 41, 1660\u20131670 (2020).","journal-title":"Carcinogenesis"},{"key":"74571_CR44","doi-asserted-by":"publisher","first-page":"107502","DOI":"10.1016\/j.celrep.2020.03.066","volume":"31","author":"S Lee","year":"2020","unstructured":"Lee, S. et al. Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer. Cell Rep. 31, 107502 (2020).","journal-title":"Cell Rep."},{"key":"74571_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"74571_CR46","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"74571_CR47","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/bioinformatics\/btt445","volume":"29","author":"M Shugay","year":"2013","unstructured":"Shugay, M., Ortiz de Mend\u00edbil, I., Vizmanos, J. L. & Novo, F. J. Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions. Bioinformatics 29, 2539\u20132546 (2013).","journal-title":"Bioinformatics"},{"key":"74571_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","volume":"32","author":"K Okonechnikov","year":"2016","unstructured":"Okonechnikov, K., Conesa, A. & Garc\u00eda-Alcalde, F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32, 292\u2013294 (2016).","journal-title":"Bioinformatics"},{"key":"74571_CR49","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532 (2012).","journal-title":"Bioinformatics"},{"key":"74571_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"74571_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"74571_CR52","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74571_CR53","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"74571_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"74571_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279\u2013284 (2001).","journal-title":"Behav. Brain Res."},{"key":"74571_CR56","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"74571_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"74571_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"74571_CR59","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865\u20132871 (2009).","journal-title":"Bioinformatics"},{"key":"74571_CR60","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","volume":"32","author":"D Risso","year":"2014","unstructured":"Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 32, 896\u2013902 (2014).","journal-title":"Nat. Biotechnol."},{"key":"74571_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74571-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:55:16Z","timestamp":1786402516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74571-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74571"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74571-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.P.C. reports the following: Grants\/Contracts to institution: Verastem and Astellas; Consulting: Verastem. None of these are related to the current study. L.M.S.S. reports research support from Theolytics, advisory role\/consulting fees from BioNTech, and travel support from 10x Genomics, both outside the scope of this work. C.H. reports the following: Research funding to the institution from the NIH, Sanofi, Avenge, Iovance, KSQ, Theolytics, BTG, Novartis, 280Bio, Astrazeneca, EMD Serono, Takeda, Obsidian, Genentech, BMS, Summit Therapeutics, Artidis and Immunogenesis and personal fees from Regeneron and stock options from Briacell, outside the submitted work. S.W. reports the following: Grants\/Contracts to institution: Astra Zeneca, AvengeBio, Bayer, Bio-Path, Clovis Oncology\/Pharm&, Daiichi Sankyo, GSK, Jazz Pharmaceuticals, Loxo, Mereo, Novartis, Nuvectis, Pfizer, Roche\/Genentech, Zentalis; Consulting: AstraZeneca, Bayer, Caris, Clovis Oncology\/Pharma&, Corcept, Daiichi Sankyo, Eisai, Gilead, GSK, Immunocore, ImmunoGen, Incyte, Lilly, Loxo, Merck, Mereo, Mersana, NGM Bio, Nuvectis, Pfizer, Roche\/Genentech, SeaGen, Verastem, Zentalis, ZielBio. None of these are related to the current study. L.W. reports grant funding from Breakthrough Cancer and serves as a member of the Scientific Advisory Board for SELLAS Life Sciences and receives compensation outside the scope of this work. Y.Y. is the founder of Polaris Consulting LLC, outside the scope of this work. A.K.S. reports the following: Research funding: Pfizer, Consulting: Onxeo, Kaida. Both are unrelated to the current study. D.M.G. reports royalty from UpToDate and Elsevier, equity interest from Johnson & Johnson, Bristol Myers Squibb, Procter and Gamble, consultant role and honorarium with Verastem. None of these are related to the current study. A.A.J. reports funding to the institution for this trial from AstraZeneca and Eli Lilly. Unrelated to this project he also reports clinical trial funding to the Institution from AstraZeneca, Merck, Imunon, Iovance, GSK, Lixte, and Macrogenics, Immatics, and paid advisory role with Macrogenics, Sentinel Bio, Iovance, RBL, and Duracyte, Guidepoint, and Gerson Lehrman Group. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8125"}}